| Literature DB >> 31250279 |
Isabelle Koob1, Anja Pickhard2, Maria Buchberger1, Melanie Boxberg3, Rudolf Reiter4, Guido Piontek1, Ulrich Straßen1.
Abstract
Pharyngocutaneous fistulae (PCF) are one of the most common complications after laryngectomy. Predisposing risk factors have been studied, yet knowledge to determine which patients are prone to developing a fistula remains scarce. This study aims to establish prognostic parameters to identify individual patients at risk for PCF development. As PCF and inflammation seem to be interwoven, this work focuses on markers able to detect an inflammatory response. We retrospectively analyzed all patients who had undergone a laryngectomy at our clinic in the years 2007 to 2017 (n = 182). Immunohistochemical expression of bradykinin type 1 and 2 receptor and vascular endothelial growth factor receptor 2 was studied in all available tumor samples. Additionally, the clinical inflammation parameters 'body temperature', 'pain', 'c-reactive protein (CRP)', and 'leucocytes' were postoperatively tracked in all patients. The times between fistula diagnosis, therapeutic approach, and hospital discharge were recorded. We found a strong correlation between inflammation and the formation of a fistula. High bradykinin 1 receptor expression in the tumor samples correlated with postoperative PCF development. Persistently elevated CRP and leukocyte levels beyond the 6th postoperative day were also risk factors. A decreased time lapse between PCF diagnosis and surgical revision clearly correlated with a shorter hospital stay. In this study, we identified a bradykinin 1 receptor positive patient group at high risk for development of PCF. We recommend close monitoring for fistula formation in these patients to ensure timely intervention.Entities:
Keywords: Bradykinin receptor; Inflammation; Laryngectomy; Pharyngocutaneous fistula; Vascular endothelial growth factor receptor
Mesh:
Substances:
Year: 2019 PMID: 31250279 PMCID: PMC7235071 DOI: 10.1007/s12105-019-01043-z
Source DB: PubMed Journal: Head Neck Pathol ISSN: 1936-055X
Overview of patient cohort
| Patient collective | |
|---|---|
| Overview | 182 (160 male/22 female) |
| Average age | 63 [95% confidence interval: 62–65] |
| PCF†/no PCF† | 45 (25%)/137 (75%) |
§RT radiotherapy; RCT radiochemotherapy
†PCF pharyngocutaneous fistula
‡ Number of valid cases; Percentage indication refers to number of valid cases
*squamous cell carcinoma
Overview of patient cohort of the immunohistochemical analysis
| Patient collective of the immunohistochemical analysis | |
|---|---|
| Overview | 156 [150 male/16 female] |
| Age | 64 [95% confidence interval: 62–65] |
†PCF pharyngocutaneous fistula
‡Number of valid cases; Percentage indication refers to number of valid cases
Additional files: Characteristics of antibodies used for immunohistochemical staining
| Antibodies | Dilusion | Manufacturer |
|---|---|---|
| Rabbit Anti-Bradykinin Receptor Type B1 | 1:100 | Thermo Fisher Waltham. MA, USA |
| Rabbit Anti-Bradykinin Receptor Type B2 | 1:100 | US Biological Salem. MA, USA |
| Rabbit Anti-VEGF Receptor 2 antibody | 1:100 | Abcam Cambridge. UK |
Additional files: Immunoreactive score
| Membrane-bound immunoreactive score = PP† + SI‡ | Cytoplasmatic score | ||||
|---|---|---|---|---|---|
| PP† | SI‡ | SI‡ | |||
| negative | 0 | negative | 0 | negative | 0 |
| < 10% | 1 | weakly positive | 1 | weakly positive | 1 |
| 10–29% | 2 | moderately positive | 2 | strongly positive | 2 |
| 30–60% | 3 | strongly positive | 3 | / | 3 |
| > 60% | 4 | / | 4 | / | 4 |
†PP percentage points: percentage of stained tumor cells
‡SI staining intensity
Fig. 1Exemplary demonstration of varied immunohistochemical staining scores for B1-R. from top to bottom: B1-R immunoreactive score negative; B1-R immunoreactive score = 2; B1-R immunoreactive score = 5
Fig. 2Exemplary demonstration of varied immunohistochemical staining scores for B2-R. from top to bottom: B2-R immunoreactive score negative; B2-R immunoreactive score = 2; B2-R immunoreactive score = 5
Fig. 3Exemplary demonstration of varied immunohistochemical staining scores for VEGF-R2. From top to bottom: VEGF-R2 immunoreactive score negative; VEGF-R2 immunoreactive score = 2; VEGF-R2 immunoreactive score = 5
Fig. 4Development of postoperative average CRP values in relation to the determined cut-off value of 6.1 mg/dl
Fig. 5Development of postoperative average leucocyte values in relation to the determined cut-off value of 8.3 G/l
Fig. 6ROC curve for CRP values on postoperative day 6–15
Fig. 7ROC curve for leucocyte values on postoperative day 6–15
Evaluation of risk factors via Chi squared test (Fisher’s exact test when applicable) and calculation of relative risks
| Risk factors | n‡ total risk factor (PCF and No-PCF) | n‡ risk factor PCF† | Significance | Relative risk for PCF |
|---|---|---|---|---|
| Overview patient collecitve | 182 (100%) | 45 (25%) | ||
| Toxicants | ||||
| Alcohol | 119 (72%) | 31 (72%) | p = 0.945 | 1.020 |
| Nicotine | 119 (72%) | 33 (75%) | p = 0.569 | 1.185 |
| Diabetes | 31 (19%) | 8 (20%) | p = 0.857 | 1.064 |
| Main tumor | n‡ = 174 | n‡ = 44 | p = 1.12 | |
| Hypopharynx | 55 (33%) | 19 (46%) | p = 0.054 | 1.667 |
| Larynx | 111 (67%) | 22 (54%) | ||
| Hypopharynx & larynx | 4 (3.5%) | 1 (4.2%) | p = 1,00eF | 1.207 |
| Thyroid gland | 4 (3.5%) | 1 (4.2%) | p = 1.00eF | 1.207 |
| Further entities | 8 (6.7%) | 1 (4.2%) | p = 1.00eF | 0.603 |
| TNM | n‡ = 174 | n‡ = 44 | ||
| T-status | ||||
| T1 | 9 (5%) | 1 (2%) | p = 0.244eF | 0.294 |
| T2 (reference) | 45 (26%) | 17 (39%) | ||
| T3 | 51 (29%) | 11 (25%) | p = 0.072 | 0.560 |
| T4 | 69 (39%) | 15 (34%) | p = 0.062 | 0.575 |
| N-status | ||||
| N0 (reference) | 85(49%) | 26 (59%) | ||
| N1 | 25 (14%) | 5 (11%) | p = 0.301 | 0.654 |
| N2 | 63 (36%) | 13 (29%) | p = 0.174 | 0.675 |
| N3 | 2 (1%) | 0 (0%) | p = 1.000eF | |
| M-status | ||||
| M0 (reference) | 170 (97%) | 43 (98%) | ||
| M1 | 5 (3%) | 1 (2%) | p = 1.000eF | 0.791 |
| RT & RCT§ | n‡ = 182 | n‡ = 45 | ||
| Previous RT§ | 20 (11%) | 4 (9%) | p = 0.786 | 0.790 |
| Previous RCT§ | 16 (9%) | 10 (22%) | p = 0.001* | 2.964* |
| Surgery related risk factors | ||||
| Voice prosthesis | 150 (86%) | 34 (77%) | p = 0.064 | 0.567 |
| Surgeon | p = 0.031* | 3.250* | ||
| Flap transplant | 21 (12%) | 6 (13%) | p = 0.664 | 1.179 |
| Radialis-flap | 18 (10%) | 5 (11%) | p = 0.775eF | 1.147 |
| Pectoralis-flap | 3 (2%) | 1 (2,5%) | p = 0.570eF | 1.376 |
| No transplant | 161(88%) | 39 (87%) | ||
| Preoperative parameters | ||||
| Anaemia | 54 (43%) | 15 (44%) | p = 0.862 | 1.053 |
| Hypothyroidism | 5 (7%) | 2 (12%) | p = 0.330 | 1.813 |
| AST/ALT > 1 | 56 (64%) | 18 (75%) | p = 0.201 | 1.661 |
Anaemia♂defined as haemoglobin < 13 g/dl for men and < 12 g/dl for women
Hypothyroidism defined as thyreoglobine stimulating hormone > 4.00 µU/ml
*Statistically significant
†PCF Pharyngocutaneous fistula
§RT radiotherapy; RCT radiochemotherapy
‡Number of valid cases; Percentage indication refers to number of valid cases
eF Fisher’s exact test
Chi squared tests (or exact Fisher’s test respectively) between PCF and morphological markers as well as PCF-risk for respective score cut-off (± CRP > 6.1 mg/dl)
| Markers | Localisation in the cell | Score | Significance | PCF-risk for markers solely | PCF-risk for CRP ≥ 6.1 mg/dl & markers |
|---|---|---|---|---|---|
| B1-R | Membrane | ≥ 2 | 0.906 | 0.219 | 0.375 |
| ≥ 3 | 0.379eF | 0.3 | 0.5 | ||
| ≥ 4 | 0.117eF | 0.444 | 1.000 | ||
| ≥ 5 | 0.036* | 0.75 | 1.000 | ||
| Cytoplasm | ≥ 1 | 0.478 | 0.247 | 0.456 | |
| = 2 | 0.176 | 0.333 | 0.333 | ||
| B2-R | Membrane | ≥ 2 | 0.112 | 0.375 | 0.6 |
| ≥ 3 | 1.000eF | 0.272 | 0.5 | ||
| ≥ 4 | 0.337eF | 0.000 | 0.000 | ||
| ≥ 5 | 0.572eF | 0.000 | 0.000 | ||
| Cytoplasm | ≥ 1 | 0.849 | 0.258 | 0.529 | |
| = 2 | 0.738 | 0.308 | 0.666 | ||
| VEGF-R2 | Membrane | ≥ 2 | 0.869 | 0.268 | 0.5 |
| ≥ 3 | 0.781eF | 0.211 | 0.5 | ||
| ≥ 4 | 0.339eF | 0.000 | 0.000 | ||
| ≥ 5 | 0.569eF | 0.000 | 0.000 | ||
| Vessels | ≥ 5/fov | 0.003* | 0.337 | 0.519 |
*Statistically significant
eF Fisher’s exact test